RecruitingNCT07096180

Clinical Observational Studies:Integrative TCM and Western Medicine for Breast Cancer

Clinical Observational Studies: Breast Cancer Treatment by Traditional Chinese and Western Medicine

Sponsor

Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation

Enrollment

200 participants

Start Date

Jan 1, 2024

Study Type

OBSERVATIONAL

Conditions

Breast Cancer

Summary

The aim of this study is to investigate the intervention of traditional Chinese medicine (TCM) in managing the side effects experienced by breast cancer patients undergoing conventional Western medical treatments, such as blood cell decline, nausea, vomiting, gastrointestinal discomfort, and overall quality of life. The study aims to establish a long-term clinical enrollment criteria and process for TCM adjuvant therapy in breast cancer. The research design will utilize a prospective cohort study and real-world cross-sectional observational research method to obtain clinical data and survival status of the patients.

Eligibility

Sex: FEMALEMin Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is observing whether women with breast cancer who use traditional Chinese medicine (TCM) alongside standard Western treatments (surgery, radiation, chemotherapy, or targeted therapy) have different health outcomes compared to those who receive only Western treatments. This is an observational study — researchers collect data without assigning anyone a specific treatment. **You may be eligible if...** - You are a woman aged 18 or older - You have been diagnosed with primary breast cancer - You are currently receiving standard Western medical treatments for your breast cancer (surgery, radiation, chemo, or targeted therapy) **You may NOT be eligible if...** - You had another type of cancer before your breast cancer diagnosis - You have not received any Western medical treatment for your breast cancer - You experience discomfort or side effects from Chinese medicine that interfere with your Western medical treatment Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGChemotherapy drug

Participants in the standard care group receive conventional chemotherapy for breast cancer according to clinical guidelines. Treatment includes 8 cycles of chemotherapy administered every 3 weeks. No Traditional Chinese Medicine (TCM) is provided in this group.

OTHERIntegrative Treatment (Chemotherapy + TCM)

Participants in the integrative care group receive conventional chemotherapy combined with Traditional Chinese Medicine (TCM) treatment. Herbal formulas are prescribed by licensed TCM physicians based on syndrome differentiation and are aimed at strengthening vital qi and harmonizing stomach function. Treatment is conducted under Taiwan's National Health Insurance coverage.

Locations(1)

Buddhist Taipei Tzu Chi General Hospital

New Taipei City, Taiwan

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07096180

Related Trials

Genomic Services Research Program

NCT025959571 location

Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

NCT052833304 locations

A Synthetic Lethality-Focused Algorithm to Identify Therapeutic Options in Advanced Metastatic Breast Cancer (SYNTHESIS-Breast)

NCT070671381 location

Social and Environmental Determinants of Breast Cancer Survivorship: the Black Breast Cancer Survivor's Intervention (BBCSI)

NCT068852031 location

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer

NCT06103864316 locations